Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2017

Open Access 01-12-2017 | Research article

Multidimensional daily diary of fatigue-fibromyalgia-17 items (MDF-fibro-17): part 2 psychometric evaluation in fibromyalgia patients

Authors: Y. Li, S. Morris, J. Cole, S. Dube’, J. A. M. Smith, C. Burbridge, T. Symonds, S. Hudgens, W. Wang

Published in: BMC Musculoskeletal Disorders | Issue 1/2017

Login to get access

Abstract

Background

The Multidimensional Daily Diary of Fatigue-Fibromyalgia-17 instrument (MDF-Fibro-17) has been developed for use in fibromyalgia (FM) clinical studies and includes 5 domains: Global Fatigue Experience, Cognitive Fatigue, Physical Fatigue, Motivation, and Impact on Function. Psychometric properties of the MDF-Fibro-17 needed to demonstrate the appropriateness of using this instrument in clinical studies are presented.

Methods

Psychometric analyses were conducted to evaluate the factor structure, reliability, validity, and responsiveness of the MDF-Fibro-17 using data from a Phase 2 clinical study of FM patients (N = 381). Confirmatory factor analyses (CFA) were performed to ensure understanding of the multidimensional domain structure, and a secondary factor analysis of the domains examined the appropriateness of calculating a total score in addition to domain scores. Longitudinal psychometric analyses (test-retest reliability and responder analysis) were also conducted on the data from Baseline to Week 6.

Results

The CFA supported the 17-item, 5 domain structure of this instrument as the best fit of the data: comparative fit index (CFI) and non-normed fit index (NNFI) were 0.997 and 0.992 respectively, standardized root mean square residual (SRMR) was 0.010 and the root mean square error of approximation (RMSEA) was 0.06. In addition, total score (CFI and NNFI both 0.95) met required standards. For the total and 5 domain scores, reliability and validity data were acceptable: test-retest and internal consistency were above 0.9; correlations were as expected with the Global Fatigue Index (GFI) (0.62-0.75), Fibromyalgia Impact Questionnaire (FIQ) Total (0.59–0.71), and 36-Item Short Form Health Survey (SF-36) vitality (VT) (0.43–0.53); and discrimination was shown using quintile scores for the GFI, FIQ Total, and Pain Numeric Rating Scale (NRS) quartiles. In addition, sensitivity to change was demonstrated with an overall mean responder score of -2.59 using anchor-based methods.

Conclusion

The MDF-Fibro-17 reliably measures 5 domains of FM-related fatigue and psychometric evaluation confirms that this measure meets or exceeds each of the predefined acceptable thresholds for evidence of reliability, validity, and responsiveness to changes in clinical status. This suggests that the MDF-Fibro-17 is an appropriate and responsive measure of FM-related fatigue in clinical studies.
Literature
1.
Humphrey L, Arbuckle R, Mease P, Williams DA, Samsoe BD, Gilbert C. Fatigue in fibromyalgia: a conceptual model informed by patient interviews. BMC Musculoskelet Disord. 2010;11:216.CrossRefPubMedPubMedCentral
2.
Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II Arthritis Rheum. 2008;58:26–35.CrossRefPubMed
3.
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 1990;33:160–72.CrossRefPubMed
4.
Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–28.CrossRefPubMed
5.
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62:600–10.CrossRef
6.
Perrot S, Winkelmann A, Dukes E, Xu X, Schaefer C, Ryan K, et al. Characteristics of patients with fibromyalgia in France and Germany. Int J Clin Pract. 2010;64:1100–8.CrossRefPubMed
7.
Schaefer C, Chandran A, Hufstader M, Baik R, McNett M, Goldenberg D, et al. The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes. 2011;9:71.CrossRefPubMedPubMedCentral
8.
Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008;59:952–60.CrossRefPubMed
9.
Burbridge C, Symonds T, Humphrey L, Arbuckle R, Hirsch I, Whelan L. Validation of the Daily Diary of Fatigue Symptoms-Fibromyalgia (DFS-Fibro). Open J Rheumatol Autoimmune Disord. 2013;3(2):92–103.
10.
Arnold LM, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial. Arthritis Res Ther. 2011;13:R86.CrossRefPubMedPubMedCentral
11.
Mease PJ, Palmer RH, Wang Y. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials. J Clin Rheumatol. 2014;20:195–202.CrossRefPubMed
12.
Morris S, Burbridge C, Symonds T, Hudgens S. Multidimensional Daily Diary of Fatigue Symptoms Fibromyalgia-17 Items (MDF-Fibro-17). Part 1: Development and Content Validity. 2015. doi:10.​1186/​s12891-017-1544-y.
13.
14.
Smith JA, Patil DL, Daniels OT, Ding YS, Gallezot JD, Henry S, et al. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2015;18:yu027.CrossRef
15.
Theravance Technical Report for the Psychometric Study of the Multidimensional Daily Diary of Fatigue Symptoms-Fibromyalgia (DFS-Fibro-17). Version 2.0. 9-22-2014. San Diego, California, Covance Market Access Services Inc. (internal report, unpublished).
16.
Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Boca Raton: Chapman & Hall/CRC Press; 2013.
17.
18.
Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef
19.
Hu L, Bentler PM. Fit indices in covariance structure modeling: sensitivity to underparameterized model misspecification. Psychol Methods. 1998;3:424.CrossRef
20.
Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model. 1999;6:1–55.CrossRef
21.
Marsh HW, Hau KT, Wen Z. In search of golden rules: Comment on hypothesis-testing approaches to setting cutoff values for fit indexes and dangers in overgeneralizing Hu and Bentler’s (1999) findings. Struct Equ Model. 2004;11:320–41.CrossRef
22.
Steiger JH, Lind JC. Statistically based tests for the number of common factors. 1980.
23.
Steiger JH. Structural model evaluation and modification: an interval estimation approach. Multivar Behav Res. 1990;25:173–80.CrossRef
24.
Nunnally JC. Psychometric theory. 2nd ed. New York: McGraw-Hill; 1978.
25.
Comrey AL, Lee HB. A first course in factor analysis. 2nd ed. Hillsdale: Lawrence Erlbaum; 1992.
26.
McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40–66.CrossRefPubMed
27.
Cohen J. Statistical power analysis for the behavioral sciences rev. Hillsdale: Lawrence Erlbaum Associates, Inc; 1977.
28.
Fayers P, Machin D. Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. West Sussex: John Wiley & Sons; 2013.
29.
Litwin MS. How to measure survey reliability and validity, 7 edn. Thousand Oaks: Sage Publications; 1995.
30.
Vaz S, Falkmer T, Passmore AE, Parsons R, Andreou P. The case for using the repeatability coefficient when calculating test-retest reliability. PLoS One. 2013;8:e73990.CrossRefPubMedPubMedCentral
31.
Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatism. 2010;62:2745–56.CrossRefPubMed
32.
Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009;36:1304–11.CrossRefPubMed
33.
Branco JC, Zachrisson O, Perrot S, Mainguy Y. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol. 2010;37:851–9.CrossRefPubMed
34.
Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ. A pooled analysis of Two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract. 2011;11:120–31.CrossRefPubMed
35.
Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:398–409.CrossRefPubMed
36.
Oh TH, Hoskin TL, Luedtke CA, Weingarten TN, Vincent A, Kim CH, et al. Predictors of clinical outcome in fibromyalgia after a brief interdisciplinary fibromyalgia treatment program: single center experience. PM&R. 2012;4:257–63.CrossRef
37.
Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012;14:R217.CrossRefPubMedPubMedCentral
38.
Pauer L, Atkinson G, Murphy TK, Petersel D, Zeiher B. Long-term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin. Clin J Pain. 2012;28:609–14.CrossRefPubMed
39.
Pouchot J, Kherani RB, Brant R, Lacaille D, Lehman AJ, Ensworth S, et al. Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. J Clin Epidemiol. 2008;61:705–13.CrossRefPubMedPubMedCentral
40.
Russell IJ, Perkins AT, Michalek JE. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, doubleGÇÉblind, placeboGÇÉcontrolled, multicenter clinical trial. Arthritis Rheumatism. 2009;60:299–309.CrossRefPubMed
41.
Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego: Academic; 1985.
42.
Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res. 1993;42:93–9.CrossRefPubMed
43.
Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36 health survey (standard & acute forms). Lincoln: QualityMetric Incorporated; 2000.
44.
Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18:728–33.PubMed
45.
Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The revised fibromyalgia impact questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11:1–14.CrossRef
46.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed
47.
McGahuey A. The Arizona sexual experience scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25–40.CrossRefPubMed
48.
Allee-Smith PJ, Winters RR, Drake A, Joslin AK. Test Review: Barkley Deficits in Executive Functioning Scale (BDEFS). J Psychoeduc Assess. 2012;31(1):80–83.
49.
Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol. 1994;16:093–104.CrossRef
50.
Gronwall DMA. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills. 1977;44:367–73.CrossRefPubMed
51.
Brown J. Some tests of the decay theory of immediate memory. Q J Exp Psychol. 1958;10:12–21.CrossRef
Metadata
Title
Multidimensional daily diary of fatigue-fibromyalgia-17 items (MDF-fibro-17): part 2 psychometric evaluation in fibromyalgia patients
Authors
Y. Li
S. Morris
J. Cole
S. Dube’
J. A. M. Smith
C. Burbridge
T. Symonds
S. Hudgens
W. Wang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2017
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-017-1545-x

Other articles of this Issue 1/2017

BMC Musculoskeletal Disorders 1/2017 Go to the issue

Research article

Implementing the Keele stratified care model for patients with low back pain: an observational impact study

Research article

Does a deep seated L5 vertebra position with respect to the iliac crests affect the accuracy of percutaneous pedicle screw placement at lumbosacral junction?

Research article

Is there a clinical benefit of additional tension band wiring in plate fixation of the symphysis?

Study protocol

Neck-specific exercises with internet-based support compared to neck-specific exercises at a physiotherapy clinic for chronic whiplash-associated disorders: study protocol of a randomized controlled multicentre trial

Study protocol

Prospective comparison of the anterior and lateral approach in hemiarthroplasty for hip fractures: a study protocol

Research article

Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial